Major bummer: Novo Nordisk’s blockbuster weight-loss drug, Wegovy (semaglutide), totally flopped in late-stage trials for Alzheimer’s. Even though the drug showed some changes in disease biomarkers, it didn’t actually slow down Alzheimer’s progression compared to a placebo. The company’s stock took a nosedive and they’re pulling the plug on these trials. Guess this “miracle” drug isn’t a miracle for everything after all! #Health #BodyHealth #Alzheimers